Stocktoria
C4 Therapeutics, Inc. CCCC
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-10-02
C4 Therapeutics, Inc. financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $35.9M | $35.6M | $20.8M | $31.1M | $45.8M | — | — |
| R&D expense | $104.2M | $110.6M | $117.7M | $117.8M | $94.7M | $78.4M | $48.1M |
| Operating income | -$115.2M | -$119.6M | -$139.0M | -$129.5M | -$82.1M | -$60.4M | -$35.5M |
| Income tax | $121,000 | $131,000 | $1.3M | $0 | $0 | -$626,000 | $804,000 |
| Net income | -$105.0M | -$105.3M | -$132.5M | -$128.2M | -$83.9M | -$66.3M | -$34.1M |
| EPS (diluted) | $-1.27 | $-1.52 | $-2.67 | $-2.62 | $-1.82 | — | — |
| Operating cash flow | -$98.7M | -$65.2M | -$106.8M | -$105.9M | -$87.0M | -$67.2M | $55.6M |
| Free cash flow | -$99.3M | -$65.3M | -$108.5M | -$111.4M | -$88.2M | -$67.9M | $54.3M |
| Cash & equivalents | $74.6M | $55.5M | $126.6M | $29.8M | $76.1M | $181.7M | $90.5M |
| Total assets | $359.1M | $349.6M | $376.5M | $430.8M | $506.8M | $400.1M | $118.3M |
| Total liabilities | $102.5M | $133.6M | $130.3M | $141.6M | $117.2M | $119.3M | $119.2M |
| Shareholders' equity | $256.6M | $216.0M | $246.1M | $289.2M | $389.6M | $280.8M | -$112.0M |
Growth · year-over-year · Revenue CAGR -5.9%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth | +1.0% | +71.4% | -33.3% | -32.1% | — | — | — |
| Free cash flow growth | — | — | — | — | — | -225.1% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.